{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:12:28Z","timestamp":1779253948163,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T00:00:00Z","timestamp":1458604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T00:00:00Z","timestamp":1458604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the safety and ocular hypotensive efficacy of 4 trabodenoson doses administered twice daily over 14 or 28 days in subjects with ocular hypertension or primary open-angle glaucoma (POAG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this multicenter, randomized, double-masked, placebo-controlled, dose-escalation Phase 2 study, patients received unilateral topical twice-daily trabodenoson (50, 100, or 200\u2009mcg) or placebo for 14 days, or 500\u2009mcg trabodenoson or placebo for 28 days. Ocular and systemic safety and tolerability were assessed by examinations, clinical and laboratory studies. Intraocular pressure (IOP) was assessed using Goldmann tonometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Trabodenoson was well tolerated; no clinically meaningful ocular or systemic side effects were identified. Trabodenoson produced a dose-dependent IOP reduction. IOP reductions in the 500\u2009mcg group were significantly greater than placebo at all time points at Day 28. Mean IOP reductions from diurnal baseline ranged from \u22123.5 to \u22125.0\u2009mmHg with a mean change of \u22124.1\u2009mmHg in the 500\u2009mcg group compared \u22121.0 to \u22122.5\u2009mmHg with a mean change of \u22121.6\u2009mmHg for the placebo group, and the Day 28 drop was significantly greater than at Day 14 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0163) indicating improvement in IOP lowering with longer treatment time. IOP remained significantly reduced 24\u2009h after the final 500\u2009mcg dose (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.048).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Twice-daily ocular doses of trabodenoson, from 50 to 500\u2009mcg, were well tolerated and showed a dose-related decrease in IOP that was statistically significant and clinically relevant at 500\u2009mcg in patients with ocular hypertension or POAG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2015.0148","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T15:20:12Z","timestamp":1458660012000},"page":"555-562","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":41,"title":["A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma"],"prefix":"10.1177","volume":"32","author":[{"given":"Jonathan S.","family":"Myers","sequence":"first","affiliation":[{"name":"Wills Eye Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth N.","family":"Sall","sequence":"additional","affiliation":[{"name":"Sall Research Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey","family":"DuBiner","sequence":"additional","affiliation":[{"name":"Eye Care Centers Management, Inc.","place":["Georgia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natanya","family":"Slomowitz","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"McVicar","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cadmus C.","family":"Rich","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.714"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0057"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.004"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12163"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2014.08.009"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704267"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1997.0296"},{"key":"e_1_3_3_12_2","first-page":"1833","article-title":"Characterization of ocular hypertension induced by adenosine agonists","volume":"37","author":"Crosson C.E.","year":"1996","unstructured":"Crosson C.E., , and Gray T. Characterization of ocular hypertension induced by adenosine agonists. Investig. Ophthalmol. Vis. Sci., 37:1833\u20131839, 1996.","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)09553-9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1994.10.379"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713689209001799"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0421"},{"key":"e_1_3_3_17_2","first-page":"3016","article-title":"Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells","volume":"43","author":"Shearer T.W.","year":"2002","unstructured":"Shearer T.W., , and Crosson C.E. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Investig. Ophthalmol. Vis. Sci., 43:3016\u20133020, 2002.","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.01.005"},{"key":"e_1_3_3_19_2","first-page":"1505","article-title":"Effects of mechanical stretching on trabecular matrix metalloproteinases","volume":"42","author":"Bradley J.M.","year":"2001","unstructured":"Bradley J.M., , Kelley M.J., , Zhu X., , Anderssohn A.M., , Alexander J.P., , and Acott T.S. Effects of mechanical stretching on trabecular matrix metalloproteinases. Investig. Ophthalmol. Vis. Sci., 42:1505\u20131513, 2001.","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_20_2","first-page":"2649","article-title":"Effect of matrix metalloproteinases activity on outflow in perfused human organ culture","volume":"39","author":"Bradley J.M.","year":"1998","unstructured":"Bradley J.M., , Vranka J., , Colvis C.M., et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Investig. Ophthalmol. Vis. Sci., 39:2649\u20132658, 1998.","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/108076803321637645"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0106"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00831-5"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.010"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0179"},{"key":"e_1_3_3_26_2","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm A.","year":"2014","unstructured":"Alm A. Latanoprost in the treatment of glaucoma. Clin. Ophthalmol., 8:1967\u20131985, 2014.","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_3_27_2","first-page":"563","article-title":"Ultrahistochemical studies on tangential sections of the trabecular meshwork in normal and glaucomatous eyes","volume":"21","author":"Lutjen-Drecoll E.","year":"1981","unstructured":"Lutjen-Drecoll E., , Futa R., , and Rohen J.W. Ultrahistochemical studies on tangential sections of the trabecular meshwork in normal and glaucomatous eyes. Investig. Ophthalmol. Vis. Sci., 21:563\u2013573, 1981.","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2008.11.025"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835(89)90027-4"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/15216540600957438"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.547091"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2015.0148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2015.0148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2015.0148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:55:42Z","timestamp":1779252942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2015.0148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,10,1]]}},"alternative-id":["10.1089\/jop.2015.0148"],"URL":"https:\/\/doi.org\/10.1089\/jop.2015.0148","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,22]]}}}